Bolt Biotherapeutics, INC Form 4 insider transactions

Bolt Biotherapeutics Director Laura Berner acquired stock options for 5,000 shares of common stock.

Bolt Biotherapeutics Director Kathleen LaPorte acquired stock options for 5,000 shares of common stock.

Jakob Dupont, a Director at Bolt Biotherapeutics, acquired 5,000 stock options with an exercise price of $4.43.

Bolt Biotherapeutics Director Brian O'Callaghan was granted stock options for 5,000 shares.

Nicole Onetto, a Director at Bolt Biotherapeutics, Inc., acquired 5,000 stock options with an exercise price of $4.43.

Bolt Biotherapeutics' President, CEO, and CFO, William P. Quinn, reported an acquisition of common stock and a grant of 20,000 employee stock options.

Bolt Biotherapeutics' Chief Operating Officer, Grant Yonehiro, was granted 10,000 employee stock options with an exercise price of $6.71 per share.

Bolt Biotherapeutics' Senior VP of Finance and PAO, Sarah Nemec, acquired common stock via an ESPP and was granted 8,000 employee stock options.

Bolt Biotherapeutics director Jakob Dupont exchanged existing stock options for new options with lower exercise prices.

Bolt Biotherapeutics director Nicole Onetto exchanged multiple underwater stock options for new options with a significantly lower exercise price of $5.44.

Bolt Biotherapeutics director Laura Berner exchanged existing stock options for new options with lower exercise prices on December 12, 2025.

Kathleen Laporte, a director at Bolt Biotherapeutics, exchanged existing stock options for new options with significantly lower exercise prices on December 12, 2025.

Bolt Biotherapeutics director Brian O'Callaghan exchanged multiple stock options with high exercise prices for new options at a significantly lower exercise price of $5.44.

Bolt Biotherapeutics Senior VP, Finance and PAO, Sarah Nemec, exchanged multiple employee stock options for new options with significantly lower exercise prices on December 12, 2025.

Bolt Biotherapeutics' Chief Operating Officer, Grant Yonehiro, exchanged multiple high-priced stock options for new options with a significantly lower exercise price of $5.44 per share.

Bolt Biotherapeutics' CEO, William P. Quinn, repriced 108,286 employee stock options, exchanging higher exercise price options for new ones at $5.44 per share.

Bolt Biotherapeutics Senior VP Sarah Nemec acquired additional common stock through an Employee Stock Purchase Plan and received a significant Restricted Stock Unit award.

Bolt Biotherapeutics' Chief Operating Officer, Grant Yonehiro, was awarded 30,000 restricted stock units, vesting in full by September 2026.

William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, increased his direct beneficial ownership by acquiring 125 shares via an ESPP and receiving a 40,000-unit restricted stock award.

Bolt Biotherapeutics Director Laura Berner was granted 1,100 stock options at an exercise price of $6.4, reflecting a recent 1-for-20 reverse stock split.

Bolt Biotherapeutics, Inc. Director Nicole Onetto was granted 1,100 stock options at an exercise price of $6.4, reflecting a recent 1-for-20 reverse stock split.

Bolt Biotherapeutics, Inc. Director Kathleen Laporte was granted 1,100 stock options at an exercise price of $6.40 per share, reflecting a recent 1-for-20 reverse stock split.

Bolt Biotherapeutics Director Brian O'Callaghan was granted 1,100 stock options with an exercise price of $6.4, reflecting a recent 1-for-20 reverse stock split.

Bolt Biotherapeutics, Inc. Director Jakob Dupont was granted 1,100 stock options at an exercise price of $6.40, reflecting a post-reverse stock split adjustment.

Jakob Dupont, a director of Bolt Biotherapeutics, acquired stock options for 20,000 shares at an exercise price of $0.351 on May 1, 2025.

Grant Yonehiro, Chief Operating Officer of Bolt Biotherapeutics, acquired 350,000 stock options on May 1, 2025, according to a Form 4 filing with the SEC.

Sarah Nemec, Senior VP of Finance and PAO at Bolt Biotherapeutics, reports acquiring shares through the Employee Stock Purchase Plan and stock options.

William P. Quinn, CEO of Bolt Biotherapeutics, reports acquiring common stock and stock options through an employee stock purchase plan and option grant.

Jakob Dupont, a director at Bolt Biotherapeutics, acquired stock options for 66,984 shares of common stock on September 3, 2024.

Grant Yonehiro, Chief Operating Officer of Bolt Biotherapeutics, acquired 155,000 stock options on July 23, 2024, according to a Form 4 filing with the SEC.